Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$15.38 USD
-0.07 (-0.45%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $15.40 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TEVA 15.38 -0.07(-0.45%)
Will TEVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Other News for TEVA
Teva management to meet with Truist
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Highlights: Strong Growth in ...
Teva Pharmaceuticals (TEVA) Reports Continued Growth in Q2 2025
Truist Hosts Influential Meeting on July 30-31 with Focus on TEVA